What medicine can replace pirfenidone?

In the treatment of idiopathic pulmonary fibrosis (IPF), pirfenidone (Pirfenidone) is currently one of the commonly used anti-fibrotic drugs. However, not all patients tolerate pirfenidone well or experience side effects while using it. At this point, the choice of alternative drugs becomes very critical. Currently, there are several drugs that can be used as alternatives to pirfenidone in the clinic, especially in treatment regimens with similar anti-fibrotic mechanisms.

The preferred alternative is nintedanib (Nintedanib ), a tyrosine kinase inhibitor also approved for the treatment of idiopathic pulmonary fibrosis. Studies have shown that nintedanib and pirfenidone have similar efficacy in slowing the decline of lung function. In contrast, the adverse reactions of nintedanib are mainly gastrointestinal symptoms such as diarrhea and nausea. For some patients who have photosensitivity or hepatotoxic reactions to pirfenidone, nintedanib may be a more suitable alternative.

In addition to nintedanib, some new anti-fibrotic drugs have also shown certain potential in the clinical research stage. For example, Ziritaxestat (GLPG1690) was once regarded as a promising drug candidate. Although its development has been terminated, related mechanism research has promoted the development of more target drugs. In addition, traditional Chinese medicine treatment regimens and certain immunomodulatory drugs (such as mycophenolate mofetil) are also used in some patients, but there is still a lack of large-scale evidence-based basis, and clinical application needs to be cautious.

When choosing alternative drugs, patients should comprehensively evaluate their condition, drug resistance, side effects, and individual treatment goals under the guidance of a physician. Some patients may still need dose adjustments or other supportive treatments when trying nintedanib. Most importantly, alternative medicines are not suitable for all patients, and individualized treatment remains a core principle in the current management of idiopathic pulmonary fibrosis.

Reference materials:https://www.esbriet.com/